AzTrials
AzTrials

Emergence AgitationEarly Phase 1NCT04142840

Dexmedetomidine and Propofol in the Treatment of Emergence Agitation

A Early Phase 1 study testing Dexmedetomidine and Propofol in people with Emergence Agitation, run by RenJi Hospital at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

1. This clinical research aims to compare the effects of dexmedetomidine and propofol on the treatment of emergence agitation in adult patients after general anesthesia. 2. Half of participants will receive dexmedetomidine while the other half will receive propofol when emergence agitation happens. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Emergence Agitation
What is being tested?
Dexmedetomidine and Propofol
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
1 siteChina
Study dates
1 Nov 2019to 30 Aug 2021
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Adult patients aged 18-65 years old after general anesthesia
  • with informed consent provided.

Who cannot join

  • age younger than 18 years or older than 65 years;
  • American Society of Anesthesiologists classification ≥Ⅲ;
  • preoperative lung dysfunction(including pneumonia,atelectasis,adult respiratory distress syndrome,acute lung injury and so on);
  • preoperative heart dysfunction(including sever cardiac coronary disease,unstable angina,LVEF≤30%,sick sinus syndrome,bradycardia:heart rate≤50bpm,second or third degree A-V block);
  • history of mental disease;
  • no informed consent provided;
Show all 11Show fewer
  • uncontrolled hypertension(baseline blood pressure:SBP≥160mmHg or DBP≥110mmHg);
  • cancers;
  • enrolled in other researches within 90 days;
  • allergic to intervening medicine.
  • BMI less than 18 or more than 30 kg/m2.

Trial locations and contacts

1 site in 1 country.

Song Zhang, MD contact

15150012530

zhangsong1031@163.com

Weifeng Yu, MD contact

18918358260

yuweifeng@renji.com

China1 site, 1 recruiting
  • Renji Hospital,Shanghai Jiao Tong University,School of Medicine

    Shanghai, Shanghai Municipality

    Song Zhang, MD, 86+15150012530, zhangsong1031@163.com

    Weifeng Yu, MD, 86+18918358260, yuweifeng@renji.com

    Recruiting

Other trials in China

About this study

Official title: Comparing the Efficacy of Dexmedetomidine and Propofol in the Treatment of Emergence Agitation Occurring in Adults After General Anesthesia: A Randomised Control Trial DP-TEA Trial

  1. This clinical research aims to compare the effects of dexmedetomidine and propofol on the treatment of emergence agitation in adult patients after general anesthesia.
  2. Half of participants will receive dexmedetomidine while the other half will receive propofol when emergence agitation happens.
Read the detailed description

As a common problem observed in pediatric patients after sevoflurane anesthesia, emergence agitations are investigated mainly in children.For adults,previous studies were almost about the efficacy of premedication on preventing emergence agitation. Once emergence agitation happens, there is still no guidelines established to recommend the medication usage in the post-anaesthesia care unit.So high-quality prospective clinical studies are required to provide evidence for emergence agitation treatment.

Dexmedetomidine and propofol are both widely used in general anesthesia and can be acquired easily.When emergence agitation occurs,both injections are common choices in daily clinical administration on emergence agitation.To the investigator's knowledge ,propofol with a very quick onset is superior for anesthesia goals, but is without analgesia effects.While dexmedetomidine can produce sedation,analgesia,anxiolysis.So the investigators propose the hypothesis here that dexmedetomidine is prior to propofol on the treatment of emergence agitation in adults patients after general anesthesia.Therefore this research is undertaken to verify the hypothesis.

Medical subject headings
Emergence Delirium

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DexmedetomidineDrug

    a selective α-2 adrenoceptor agonist which is widely used as an adjuvant to general anesthesia

  • PropofolDrug

    a short -acting medication that result in a decreased level of consciousness and lack of memory for events,widely used including the starting and maintenance of general anesthesia.

Study groups in NCT04142840
Study groupRoleWhat they receive
Dexmedetomidine GroupExperimentalGeneral anesthesia will be maintained by sevoflurane and remifentanil. End-tidal carbon dioxide will be controlled between 35 mmHg to 40 mmHg.Mean blood pressure(MAP) will be administrated between 80% and 120% of the baseline.Heart rate is going to be maintained between 50-100 beats per minute. In consultation with the surgeons and 5 minutes prior to the departure of the operating room,all the anesthesia agents are discontinued and the patient will be transferred to the post-anaesthesia care unit.And reversal agents are given to antagonize the residual muscular relaxant.Once emergence agitation occurs,the patient assigned to the dexmedetomidine group will be infused with a single dose of 0.7ug/kg dexmedetomidine.
Receives: Drug: Dexmedetomidine
Propofol GroupActive comparatorGeneral anesthesia will be maintained by sevoflurane and remifentanil. End-tidal carbon dioxide will be controlled between 35 mmHg to 40 mmHg.Mean blood pressure(MAP) will be administrated between 80% and 120% of the baseline.Heart rate is going to be maintained between 50-100 beats per minute. In consultation with the surgeons and 5 minutes prior to the departure of the operating room,all the anesthesia agents are discontinued and the patient will be transferred to the post-anaesthesia care unit.And reversal agents are given to antagonize the residual muscular relaxant.Once emergence agitation occurs,the patient assigned to the propofol group will be infused with a single dose of 0.5mg/kg propofol.
Receives: Drug: Propofol

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The recurrence rate of emergence agitation assessed by the Riker Sedation-Agitation Scale after the treatment of each group.

    1. The Riker Sedation-Agitation Scale is raging from a maximum value of 7 to a minimum value of 1.Lower scores mean a better outcome.
    2. A Riker Sedation-Agitation scale score of 5 or more than 5 will be considered as emergence agitation.

    Measured: 1 day

Secondary outcomes (7)
  1. Riker Sedation-Agitation Scale scores before and after intervention;

    Riker Sedation-Agitation Scale is raging from a maximum value of 7 to a minimum value of 1.Lower scores mean a better outcome.

    Measured: 1 day

  2. Heart rate before and after intervention;

    Heart rate wil be recorded in beats per minute.

    Measured: 1 day

  3. The consumption of sufentanil in the post-anaesthesia care unit;

    During the procedure,a dose of 0.01ug/kg sulfentanil will be given when numeric rating scale scores≥ 5 scores or the patient has a analgesia request; Numeric rating scale,with a maximum value of 10 and a minimum value of 0,is specifically as follows:0-3,slight pain;4-7,moderate pain;8-10,sever pain.Lower scores mean a better outcome.

    Measured: 1 day

  4. Nausea and vomiting scores when leaving the post-anesthesia care unit.

    According the following scale with a maximum value of 3 and a minimum value of 0,is specifically as follows:0,no nausea;1,mild nausea;2,sever nausea requiring antiemetics;3,retching,vomiting or both.Lower scores mean a better outcome.

    Measured: 1 day

  5. Duration in the post-anaesthesia care unit

    The total time from entering the post-anaesthesia care unit to leaving the post-anaesthesia care unit.

    Measured: 1 day

  6. Recovering quality: recovery scale

    The recovering quality is evaluated by the 40-item quality of recovery scale,with a maximum value of 200 and a minimum value of 0.Higher scores mean a better outcome.

    Measured: 24 hours after surgery.

  7. Mean blood pressure before and after intervention;

    Mean blood pressure will be recorded in millimeters of mercury.

    Measured: 1 day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Oct 2019
  2. Study start1 Nov 2019
  3. Primary completion30 Aug 2021 (estimated)
  4. Study completion30 Aug 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04142840
Sponsor's protocol ID
DP-TEA Trial
Status last verified
Oct 2019
First submitted
19 Oct 2019
Last updated
14 Jan 2020
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Feng Z, Shi X, Yan X, Zhu Y, Gu J, Zhu H, Yu W, Zhang S. Comparing the effects of dexmedetomidine versus propofol on the treatment of emergence agitation in adult patients after general anesthesia: study protocol for a randomized, superiority, controlled trial (DP-TEA Trial). Trials. 2021 Nov 16;22(1):811. doi: 10.1186/s13063-021-05743-2.

    PubMed 34784941

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Dexmedetomidine and Propofol in people with Emergence Agitation, run by RenJi Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 14 Jan 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Song Zhang, MD (15150012530, zhangsong1031@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The recurrence rate of emergence agitation assessed by the Riker Sedation-Agitation Scale after the treatment of each group. (time frame: 1 day). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04142840, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jan 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in